Diagnostic and Prognostic Potentials of Long Noncoding RNA ELF3-AS1 in Glioma Patients

Abstract

Objective. Accumulating evidence implies that long noncoding RNAs (lncRNAs) play a crucial role in predicting survival for glioma patients. However, the potential function of lncRNA ELF3-antisense RNA 1 (ELF3-AS1) in tumors remained largely unclear. The aim of this study was to explore the expression of lncRNA ELF3-antisense RNA 1 (ELF3-AS1) and evaluate its functions in glioma patients. Patients and Methods. ELF3-AS1 expressions were examined by RT-PCR in 182 pairs of glioma specimens and adjacent normal tissues. The receiver operating characteristic (ROC) curve was performed to estimate the diagnostic value of ELF3-AS1. The chi-square tests were used to examine the associations between ELF3-AS1 expression and the clinicopathological characters. The overall survival (OS) and disease-free survival (DFS) were analyzed by log-rank test, and survival curves were plotted according to Kaplan-Meier. The prognostic value of the ELF3-AS1 expression in glioma patients was further analyzed using univariate and multivariate Cox regression analyses. Loss-of-function assays were performed to determine the potential function of ELF3-AS1 on the proliferation and invasion of glioma cells. Results. The ELF3-AS1 expression level was significantly higher in glioma specimens compared with adjacent nontumor specimens (p<0.01). A high expression of ELF3-AS1 was shown to be associated with the WHO grade (p=0.023) and KPS score (p=0.012). ROC assays revealed that high ELF3-AS1 expression had an AUC value of 0.8073 (95% CI: 0.7610 to 0.8535) for glioma. Using the Kaplan-Meier analysis, we found that patients with a high ELF3-AS1 expression had significantly poor OS (p=0.006) and DFS (p=0.0002). In a multivariate Cox model, we confirmed that ELF3-AS1 expression was an independent poor prognostic factor for glioma patients. The functional assay revealed that knockdown of ELF3-AS1 suppressed the proliferation and invasion of glioma cells. Conclusions. Our findings confirmed that ELF3-AS1 functions as an oncogene in glioma and indicated that ELF3-AS1 is not only an important prognostic marker but also a potential therapy target for glioma.

ELF3‐AS1 contributes to gastric cancer progression by binding to hnRNPK and induces thrombocytosis in peripheral blood

“…In NSCLC and glioma studies reported in the literature, the expression of ELF3‐AS1 did not differ between the sexes. 20 , 21 We plan to collect more samples to clarify this issue. Guo reported that ELF3‐AS1 could promote bladder cancer cell viability, migration, and xenograft tumor growth, and research into the mechanism showed that ELF3‐AS1 can interact with KLF8 to increase MMP9 expression.…”

“…The lncRNA ELF3‐AS1, also known as SCAT7, is an ELF3 antisense RNA1. Several articles later reported that ELF3‐AS1 plays oncogenic roles in bladder cancer, 19 non–small cell lung cancer (NSCLC), 20 glioma, 21 osteosarcoma, 22 and oral squamous cell cancer. 23 In this study, we investigated the effect of ELF3‐AS1 on the function of GC cells and explored the precise mechanism of its effects.…”

Ferroptosis-Related Long Non-Coding RNA signature predicts the prognosis of Head and neck squamous cell carcinoma

“…lncRNA ELF3-antisense RNA 1 (ELF3-AS1) promotes the proliferation of oral squamous cell carcinoma (OSCC) cells by disrupting glucose metabolism. Overall, over-expression of ELF3-AS1 conferred poor OS of OSCC patients 29 , 30 . Similarly, one recent study reported that AL161431.1 target and binds miR-1252-5p, inhibiting MAPK signaling in endometrial carcinoma cells 31 .…”

LncRNA ELF3-AS1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma

“…ELF3-AS1 promotes cancer cell invasion and migration through downregulation of miR-212 by methylation in NSCLC [14]. ELF3-AS1 is not only an important prognostic marker, but also a potential therapeutic target for glioma [15]. In this study, based on GESA, ELF3-AS1 was related to pathways including GPCR-radioligand binding, M phase, Class A/1 (rhodopsin-like receptors), cell cycle checkpoints, translation, mitotic metaphase and anaphase, signaling by robo receptors, keratinization, and rRNA processing.…”

“…ELF3-AS1 is upregulated in nonsmall cell lung cancer (NSCLC) [14]. ELF3-AS1 is a prognostic marker and potential therapeutic target for gliomas [15]. However, the correlation between ELF3-AS1 and HCC has not been studied.…”